Jon Faldasz/LinkedIn
Nov 21, 2025, 08:55
Jon Faldasz: Why Aren’t We Better at Achieving Therapeutic Warfarin Control?
Jon Faldasz, Senior Director of Product and Customer Experience at InsightRX, posted on LinkedIn:
”Ok I know warfarin is the stinky kid in the corner, but it’s not going anywhere. So why aren’t we better at achieving time in therapeutic range?
Could it be:
– We think that 40% time in range is “good enough”? (data argues otherwise)
– Low warfarin use means we think this problem isn’t significant (patients would argue otherwise)
– We think that the problem is unsolvable? (Anticoagulation specialists argue otherwise)
I would love to get some comments to bring with me to the Anticoagulation Forum Stewardship Summit. Don’t make me call you out, people.”
Stay updated with Hemostasis Today.
-
Sep 6, 2026, 05:58Mohamed F Doheim: ‘Stroke as a Symphony’ – Rethinking Decision-Making in Acute Ischemic Stroke
-
Sep 6, 2026, 05:26Yousef Hindi: Unprovoked Left Renal Vein Thrombosis and Severe IDA – Long-Term Resolution and Dual-Energy CT Findings
-
Sep 6, 2026, 05:18Robert Brown: Standardizing Amniotic Fluid Embolism Diagnosis – SMFM and AFE Foundation Criteria
-
Sep 6, 2026, 04:45Mohammed Al Kanan: Early Identification of VTE Risk in Lung Cancer Patients
-
Sep 6, 2026, 04:38M. Ibrahim Siddique: Does Routine Triple Therapy Pay Off After Anterior STEMI?
-
Sep 6, 2026, 04:29Sandra Revill Tremulis: The Lp(a)HORIZON Topline Results Raise Important Questions Beyond Simply ‘Does Lowering Lp(a) Work?’
-
Sep 5, 2026, 19:20Yubrine Moraa Gachemba: BETULA Adds New Evidence for Catheter-Directed Thrombolysis in PE
-
Sep 5, 2026, 19:18John R. Mehall: The Importance of Anticoagulation Management in ECMO
-
Sep 5, 2026, 19:16Thirunavukkarasu Angappan: Why Hemophilia B Still Needs Both Plasma-Derived and Recombinant Factor IX